These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19185642)

  • 1. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
    Cesari M; Kritchevsky SB; Atkinson HH; Penninx BW; Di Bari M; Tracy RP; Pahor M
    Am Heart J; 2009 Feb; 157(2):334.e1-8. PubMed ID: 19185642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
    Cesari M; Pedone C; Incalzi RA; Pahor M
    J Am Med Dir Assoc; 2010 Jan; 11(1):26-32. PubMed ID: 20129212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile.
    Giovannini S; Cesari M; Marzetti E; Leeuwenburgh C; Maggio M; Pahor M
    J Nutr Health Aging; 2010 Jun; 14(6):457-60. PubMed ID: 20617288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.
    Pahor M; Franse LV; Deitcher SR; Cushman WC; Johnson KC; Shorr RI; Kottke-Marchant K; Tracy RP; Somes GW; Applegate WB
    Circulation; 2002 Jan; 105(4):457-61. PubMed ID: 11815428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
    van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
    Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
    Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
    Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
    J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD.
    Shrikrishna D; Tanner RJ; Lee JY; Natanek A; Lewis A; Murphy PB; Hart N; Moxham J; Montgomery HE; Kemp PR; Polkey MI; Hopkinson NS
    Chest; 2014 Oct; 146(4):932-940. PubMed ID: 24556825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans.
    Derad I; Otterbein A; Mölle M; Pietrowsky R; Born J; Fehm HL
    J Hypertens; 1996 Nov; 14(11):1309-15. PubMed ID: 8934359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril.
    Galatius-Jensen S; Wroblewski H; Emmeluth C; Bie P; Haunsø S; Kastrup J
    Cardiovasc Res; 1996 Dec; 32(6):1148-54. PubMed ID: 9015418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria.
    Gasic S; Wagner OF; Fasching P; Ludwig C; Veitl M; Kapiotis S; Jilma B
    Am J Hypertens; 1999 Feb; 12(2 Pt 1):217-22. PubMed ID: 10090351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q; Larouche I; Schiffrin EL
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients.
    Hansson L; Forslund T; Höglund C; Istad H; Lederballe-Pedersen O; Kristinsson A; Segaard E; Svensson A; Aärynen M; Wahrenberg H; Wennersten G; Kjellström T
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):1-5. PubMed ID: 8797128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
    Hayek T; Attias J; Coleman R; Brodsky S; Smith J; Breslow JL; Keidar S
    Cardiovasc Res; 1999 Dec; 44(3):579-87. PubMed ID: 10690290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
    Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
    J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosinopril: a new generation of angiotensin-converting enzyme inhibitors.
    Weber MA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 10():S7-12. PubMed ID: 1283429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients.
    van de Wal RM; Gansevoort RT; van der Harst P; Boomsma F; Thijs Plokker HW; van Veldhuisen DJ; de Jong PE; van Gilst WH; Voors AA
    Hypertension; 2006 Nov; 48(5):870-6. PubMed ID: 17000930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.